Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
145 results about "Gelatinase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In biology and chemistry, gelatinase is a proteolytic enzyme that allows a living organism to hydrolyse gelatin into its sub-compounds (polypeptides, peptides, and amino acids) that can cross the cell membrane and be used by the organism. It is not a pepsin.
Determination of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Diagnostic Marker for Renal Disorders
Methods for diagnosing renal disorders by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.
Owner:ANTIBODYSHOP
Free NGAL as a biomarker for cancer
Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer.
Owner:CHILDRENS MEDICAL CENT CORP
Detection kit of latex particle enhanced neutrophil gelatinase-associated lipid transfer protein
ActiveCN102253217AImprove accuracyImprove anti-interference abilityColor/spectral properties measurementsBiological testingSerum igeLatex particle
The invention provides a detection kit of a latex particle enhanced neutrophil gelatinase-associated lipid transfer protein and a preparation method thereof. The content of the neutrophil gelatinase-associated lipid transfer protein in urines, serums or blood plasmas of humans can be detected by the kit of the invention. Diameters of latex particles of the latex particle enhanced neutrophil gelatinase-associated lipid transfer protein are from 30nm to 220 nm. The kit of the invention has the advantages of good specificity, high sensitivity, strong anti-interference capability and the like.
Owner:WUHAN LIFE ORIGIN BIOTECH LTD
Antibodies to matrix metalloproteinase 9
ActiveUS20130224210A1Antibacterial agentsOrganic active ingredientsHeavy chainAntigen Binding Fragment
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
Owner:GILEAD BIOLOGICS
Kit for detecting content of neutrophil gelatinase-associated lipocalin (NGAL)
ActiveCN104198732AComposition is simpleGood test sensitivityBiological testingLatex particlePolyethylene glycol
The invention discloses a kit for detecting the content of neutrophil gelatinase-associated lipocalin (NGAL). The kit comprises a reagent R1, a reagent R2 and an NGAL reagent reference standard substance, wherein the reagent R1 comprises the following components: 10mM-100mM of Tris, 50mM-200mM of NaCl, 0.05%-1% of BSA (Bovine Serum Albumin), 0.01%-0.1% of Tween-20, 0.5%-3% of PEG (Polyethylene Glycol) and 0.1% of NaN3; the reagent R2 comprises the following components: 10mM-100mM of Tris, 50mM-200mM of NaCl, 0.05%-1% of BSA, 0.01%-0.1% of Tween-20, 0.1% of NaN3, 1%-10% of saccharose and 0.1%-1% of NGAL antibody sensitization latex particles; the NGAL reagent reference standard substance comprises the following components: 10mM-100mM of Tris, 50mM-200mM of NaCl, 0.05%-1% of BSA, 0.01%-0.1% of Tween-20, 0.5mM-5mM of EDTA (ethylenediamine tetraacetic acid) and 0.1% of NaN3. The kit is simple in reagent composition, high in test sensitivity, wide in linear range, high in stability, low in test cost, high in accuracy and convenient to popularize.
Owner:NINGBO RUI BIO TECH
Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising the same
The invention concerns a peptide extract of lupine (lupinus) characterised in that it has a metalloprotease inhibiting activity, in particular collagenase and gelatinase. The invention also concerns a pharmaceutical, cosmetic or nutritional composition comprising a peptide extract, optionally an inert carrier, in particular for treating humans or mammals suffering from a condition or disease related to excessive degeneration of support by a metalloprotease.
Owner:PHARMASCI LAB
Neutrophil gelatinase-associated lipocalin (NGAL) protein level ELISA kit
ActiveCN106814193ASpeed up dissociationColor/spectral properties measurementsBiological testingElisa kitBinding site
Disclosed is a neutrophil gelatinase-associated lipocalin (NGAL) protein level ELISA kit which is composed of a reagent I and a reagent II. The reagent I comprises a slow-release agent and a denaturant; the reagent II comprises latex particles coated with NGAL antibodies. Aggregated protein is denatured to some extent after being added with the denaturant, physical and (or) chemical binding site is exposed, chemical binding action of the chemical binding site is fractured through sulfydryl dissociation agent , while physical binding action of the physical binding site is dispersed by surface active agent, so that the aggregated protein is disaggregated. Therefore, it is quite important to choose the appropriate types and concentrations of denaturant, sulfydryl dissociation agent, and surface active agent; the aggregate is disaggregated without interference on following immunological detection. According to the method, the the appropriate types and concentrations of denaturant, sulfydryl dissociation agent and surface active agent are determined and chosen specifically, which solves the technical problem above.
Owner:NINGBO MEDICAL SYSTEM BIOTECHNOLOGY CO LTD
Method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in sample
The invention relates to a method for detecting neutrophil gelatinase-associated lipocalin (NGAL) in a sample. The method comprises the following steps of: reacting an antibody of the NGAL with human NGAL of a specimen to be detected to form a compound which causes turbidity change; characterizing the change by using light projection intensity or light scattering intensity; and finding out the content of the human NGAL in the specimen to be detected from the concentration of the NGAL standard product and a standard curve of corresponding light scattering intensity or light transmission intensity. The method has the advantages of high sensitivity, high recovery rate and good repeatability, and a detection measure having the advantages of simplicity, convenience, good repeatability, strong adaptability and high speed is determined for measuring the NGAL in the samples of urine or blood plasma, and the like.
Owner:WUHAN LIFE ORIGIN BIOTECH LTD
Methods, Devices and Kits for Detecting or Monitoring Acute Kidney Injury
ActiveUS20110287455A1High sensitivityEasy to detectPeptide librariesChemiluminescene/bioluminescenceEpitopeGelatinase
Methods for detecting acute kidney injury in an individual comprise (a) contacting a body fluid sample from the individual with an assay device including neutrophil gelatinase-associated lipocalin (NGAL) antibody and a detectable label, to allow complexing of NGAL protein in the sample with NGAL antibody, and determining an amount of complex formed between NGAL protein from the sample and NGAL antibody in the assay device using the detectable label, wherein NGAL antibody in the device has binding capacity with more than two NGAL protein epitopes, and wherein the amount of the formed complex represents a level of acute kidney injury. Methods for determining an origin of NGAL protein in a sample from an individual include the step of determining relative amounts of monomeric, dimeric and heterodimeric forms of NGAL protein in the sample and allow improved diagnosis and therefore better targeted treatment.
Owner:FUTURE MEDICAL DIAGNOSTICS CO LTD
Neutrophil gelatinase-associated lipocalin (NGAL) assay kit (latex-enhanced immunoturbidimetry)
ActiveCN102680698AHigh detection sensitivityEasy to operateBiological testingMicrosphereImmunoturbidimetry
The invention relates to a kit for assaying NGAL in serum, and provides an NGAL assay kit suitable for a full-automatic biochemical analyzer and a special protein analyzer. The technical scheme includes that the NGAL assay kit comprises reagent R1, reagent R2 and a calibrator, wherein the reagent R1 is composed of a buffer solution, an accelerator, a surfactant and the balance purified water; the reagent R2 is composed of a buffer solution and latex microspheres combined with anti-human NGAL antibodies; and the calibrator is composed of a buffer solution, a stabilizer, a preservative, a certain amount of pure recombinant human NGAL required by concentration, and the balance purified water. The NGAL content in the serum can be quickly assayed through the reagent combination.
Owner:NANJING NORMAN BIOLOGICAL TECH
Method for diagnosing, evaluating or testing cancer and foreseeing cancer severity
The invention relates to a method for diagnosing, evaluating or testing a cancer and foreseeing the severity of the cancer. The testing method comprises the following steps: an antibody of anti-human tropic neutrophil gelatinase-associated lipocalin (NGAL) is reacted with the human NGAL of a specimen to be tested to form a compound which causes turbidity change; light protection intensity or light scattering intensity is used for presenting the change; the human NGAL content of the specimen to be tested is tested through a standard curve of the concentration of human NGAL standard to relevant light protection intensity or light scattering intensity; and finally the cancer severity is measured based on the tested NGAL content. The method has the advantages of high flexibility, high recovery and good repetitiveness, determines a testing method with great convenience, good repetitiveness and strong suitability for the NGAL in urine or blood plasma of a cancer patient, and provides possibility for the clinical directive function of human NGAL and further research of the functions of the human NGAL.
Owner:CUSABIO TECH LLC
Latex enhanced immunoturbidimetry NGAL detection kit
InactiveCN104215769AGuaranteed uniformityGuaranteed stabilityBiological testingLatex particleNGAL Protein
The invention provides a latex enhanced immunoturbidimetry NGAL detection kit. The latex enhanced immunoturbidimetry NGAL detection kit comprises a reagent R1, a reagent R2 and a standard substance; the reagent R1 comprises a buffer solution, a surfactant, a chelating agent, an accelerator and an antiseptic; the reagent R2 comprises the buffer solution, NGAL antibody-coated latex particles, and an unrelated protein; and the standard substance is a solution containing 6 NGAL recombinant protein concentration gradients. Compared with kits in the prior art, the neutral granulocyte gelatinase related lipid transporter content detection kit used on a fully automatic biochemical analyzer has the advantages of rapid determination of the content of the NGAL in urine or blood plasma, guarantee of the sensitivity and the linearity, and improved sensitivity, accuracy and linearity of the determination result.
Owner:上海睿康生物科技有限公司
Diagnosis and monitoring of chronic renal disease using ngal
InactiveUS20100234765A1Difficult to levelImprove the level ofDisease diagnosisDiagnostic recording/measuringRegimenProper treatment
A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.
Owner:BARASCH JONATHAN MATTHEW +3
Neutrophil gelatinase associated lipocalin (NGAL) chemiluminescence detection kit
InactiveCN102967714AOvercome the greater influence of blood lipid concentrationHigh sensitivityChemiluminescene/bioluminescenceBiological testingElisa methodBiology
The invention discloses a neutrophil gelatinase associated lipocalin (NGAL) chemiluminescence detection kit. The kit comprises the components of a standard substance of NGAL, an NGAL monoclonal antibody labeled by horseradish peroxidase, magnetic particles coated by the NGAL monoclonal antibody, a white non-transparent microwell plate, washing liquid, and chemiluminescence substrates A and B. The kit provided by the invention can be used for detecting the content of the NGAL in blood serum of a patient, and has important guiding significance to the detections on premature kidney diseases and injures. Compared with the conventional ELISA (Enzyme Linked Immunosorbent Assay) method, the NGAL chemiluminescence detection kit provided by the invention has the characteristics of being high in sensitivity and good in specificity and overcoming the large influence of immunoturbidimetry by blood fat concentration, and has the advantages of high stability, reliability and accuracy, security and environment friendliness, simplicity and convenience in operation and the like.
Owner:天津市协和医药科技集团有限公司
Process for separating protein, apple polyphenol, apple starch and pigment from apple juice
ActiveCN1763216AEfficient removalGood filtrate conditionOrganic compounds purification/separation/stabilisationUltrafiltrationPectinaseCellulose
The present invention is one kind of tubular ultrafiltering and clarification and reeling ultrafiltering and separation combined process for separating apple protein, apple polyphenol, apple starch and pigment from apple juice. The process can lower the color value of apple juice, raise the quality one apple juice and utilize apple juice comprehensively. The process includes the steps of material screening, washing, drying, crushing and squeezing to obtain apple juice and apple residue, pasteurizing, enzymolysis with pectase and gelatinase, tubular ultrafiltering and clarification to obtain clear juice, great molecular weight protein, cellulose, starch and pectin, reeling ultrafiltering and separation to obtain purified juice and concentrate with rich apple polyphenol, small molecular weight protein and pigment, treating clear apple juice to eliminate pesticide residue and heavy metal and concentration, and ultrahigh temperature short-time sterilization of apple juice.
Owner:SANDA FILM SCI & TECH XIAMEN
Detection kit for neutrophil gelatinase-associated lipocalin
The invention discloses a detection kit for neutrophil gelatinase-associated lipocalin. The detection kit comprises a detection liquid and a standard substance, wherein the detection liquid comprises latex particles coupled with an anti-human neutrophil gelatinase-associated lipocalin antibody; the standard substance is naturally configured recombinant neutrophil gelatinase-associated lipocalin. The detection kit measures the content of the neutrophil gelatinase-associated lipocalin through a latex particle intensified immunity turbidity, and compared with the traditional NGAL detection kit, the detection kit has the advantages of high detection sensitivity, high simpleness in operation, good repeatability and short time consumption, does not need sample pretreatment, and can be used for a fully automatic biochemical analyzer.
Owner:FAPON BIOTECH INC
Immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and preparation method thereof
InactiveCN102662064AHighlight substantive featuresSignificant progressBiological testingLipocalinGelatinase
The invention relates to an immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and a preparation method thereof; an application liquid bottle, an antibody suspending liquid bottle and a standard substance bottle are placed in a box body; application liquid is arranged in the application liquid bottle, and comprises the following components of: 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative, 1 percent to 20 percent of sodium chloride and 20mmol / l to 200mmol / l of buffer solution; the antibody suspending liquid bottle contains emulsion suspension which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, and the emulsion suspension has the following components of: 0.05 percent to 0.5 percent of emulsion which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative and 20mmol / l to 200mmol / l of buffer solution; and the standard substance bottle contains the standard substances of the lipid carrier protein related to the neutrophils gelatinase. According to the invention, the mass quantitative detection on a biochemical instrument is realized.
Owner:苏州照康生物技术有限公司
Oil-degradation oil-and-salt tolerance bacterial strain, and screening method and application thereof
ActiveCN103205378AGood oil and salt resistanceFast growthBacteriaContaminated soil reclamationEscherichia coliScreening method
The invention relates to an oil-degradation oil-and-salt tolerance bacterial strain which is named as SY-1. The systematic name of the SY-1 is Escherichia coli, the file number is CGMCC (China General Microbiological Culture Collection Center No.7075, the file date is December 31, 2012, the file address is the Micro-organism Study of Chinese Academy of Sciences, No.3, No.1 Beichen west road, Chaoyang district, Beijing city, and the file unit is China General Microbiological Culture Collection Center. The oil-degradation oil-and-salt tolerance bacterial strain is good in oil and salt tolerance, is Gram-negative bacterium shaped in short rhabditiform and with flagellum and no spores and active, is in citrate and glucose ammonium salt positive property and can generate catalase without gelatinase. The bacterial strain is fast in growth, can grow in oil used as unique carbon source, and has the advantages of oil degradation.
Owner:航天圣诺(北京)环保科技有限公司
Method for capturing and identifying fetal nucleated red blood cells in a microfluidic chip
InactiveCN108753573AIncreased chance of collisionImprove capture abilityBioreactor/fermenter combinationsBiological substance pretreatmentsBiotin-streptavidin complexCell layer
The invention provides a method for capturing and identifying fetal nucleated red blood cells in a microfluidic chip. The method comprises the following steps: 1, synthesizing gelatin nanoparticles bya two-step solvent removal method and preparing into a precursor liquid, and then introducing into a microfluidic chip to form a nanometer coating on the inner wall thereof, wherein the microfluidicchip comprises a plurality of serpentine main channels and the plurality of fish bone units; 2, modifying streptavidin on the nanometer coating by a chemical modification method, then grafting a biotin-modified antibody; 3, separating a mononuclear cell layer containing fetal nucleated red blood cells from peripheral blood by density-gradient centrifugation; 4, allowing mononuclear cell suspensionto flow into the microfluidic chip at a certain flow rate for capturing; 5, introducing a certain concentration of gelatinase into the microfluidic chip that captures fetal nucleated red blood cells,releasing fetal nucleated red blood cells by degrading the nanometer coating; and 6, identifying captured fetal nucleated red blood cells by using specific antibodies.
Owner:WUHAN UNIV
SCREENING METHOD USING GELATINASE-MEDIATED EphA4 CLEAVAGE REACTION AS AN INDICATOR
ActiveUS20130288278A1Promotes and inhibits EphA cleavage reactionEnhances and reduces spine formationCompound screeningApoptosis detectionGelatinaseScreening method
The object of the present invention is to provide a method for screening a substance that affects gelatinase-mediated EphA4 processing. The present invention provides a method for screening a substance that affects gelatinase-mediated EphA4 processing, which comprises the steps of: (a) allowing a first biological composition containing gelatinase or a biologically active fragment thereof to be contacted with a second biological composition containing EphA4 in the presence and absence of a candidate substance; (b) measuring the presence or amount of the EphA4 ectodomain and / or endodomain fragment; and (c) selecting the candidate substance as a substance that affects gelatinase-mediated EphA4 processing if the results of the step (b) measured in the presence of the candidate substance are changed in comparison with the results of the step (b) measured in the absence of the candidate substance.
Owner:EISIA R&D MANAGEMENT CO LTD
New lactic bacteria useful as probiotics
InactiveUS20080063666A1Pleasant flavorHealthy digestion and intestineBiocideBacterial antigen ingredientsDiseaseAmpicillin
An isolated strain of Enterococcus faecalis GALT deposited under number C E C T 7121 of the group of lactic bacteria is disclosed, which is capable of surviving and colonizing the gastrointestinal tract of humans and / or animals and showing beneficial probiotic activity for the health of humans and animals. The strain E. faecalis GALT and / or a culture supernatant and / or metabolites thereof shows no in vitro multiresistance to antibiotics of common use in human clinics as glycopeptides, such as vancomycin, teicoplanine; carbapenemes, such as impipenem, meropenem; and ampicillin. The strain E. faecalis GALT contains no red blood cell-destroying hemolysins of human, ovine and equine origin; and it does not produce any gelatinase, DNase and decarboxylases. The strain E. faecalis GALT is useful for the preparation of a composition intended for the treatment and / or prophylaxis of disorders associated with colonization by pathogenic microorganisms of the gastrointestinal tract; for use as a regulator of the immune response in human and animals, as well as for the preparation of a composition. The invention is also directed to methods and uses of the strain E. faecalis GALT.
Owner:ALLENDE MIGUEL ANGEL GARCIA
Mouse anti-human neutrophil gelatinase-associated lipocalin (NGAL) monoclonal antibodies and hybridoma cell strains and application thereof
InactiveCN102776153AImmunoglobulins against animals/humansMicroorganism based processesEpitopeLipocalin
The invention discloses a hybridoma cell strain 3B1 and a hybridoma cell strain 4C2 and a mouse anti-human NGAL monoclonal antibody 3B1 and a mouse anti-human NGAL monoclonal antibody4C2 produced respectively. The two kinds of monoclonal antibodies belong to a same immunoglobulin G (IgG) 2a subclass, but identify various epitopes and can perform specific binding to NGAL recombinant protein with amino acid sequences represented by SEQ ID NO.1. The two monoclonal antibodies can be applied to detect the concentration of the NGAL in human body fluids and have significant application prospect.
Owner:GETEIN BIOTECH
Neutrophil gelatinase-associated lipocalin determination kit
InactiveCN106093422ARapid responseEliminate distractionsDisease diagnosisBiological testingFully automaticAbsorbance
The invention discloses a neutrophil gelatinase-associated lipocalin determination kit. The kit comprises a reagent R1 and a reagent R2 which are liquid components and are mutually independent, the reagent R1 comprises a buffer solution, inorganic salt ions, an accelerator, a chelating agent, a stabilizer, an antiseptic and an anti-humanr heumatoid factor antibody, and the reagent R2 comprises the buffer solution, the stabilizer, a suspending aid, a surfactant, the antiseptic and a latex coated anti-human neutrophil gelatinase-associated lipocalin. The preparation method comprises the following steps: preparing the reagents according to the component content; mixing a sample to be determined with the reagent R1 and the reagent R2 to fully react the sample to be determined with the reagent R1 and the reagent R2; determining the absorbance difference by using a fully-automatic biochemical analyzer after the reaction; and calculating the concentration of neutrophil gelatinase-associated lipocalin in the sample according to the absorbance change value. The kit has high accuracy.
Owner:ANHUI IPROCOM BIOTECH CO LTD
B cell epitope peptide of human neutrophil gelatinase associated lipocalin and application thereof
ActiveCN102775473AHigh purityHigh potencyImmunoglobulins against animals/humansMicroorganism based processesImmune complex depositionNGAL Protein
The invention belongs to the medical field and particularly relates to an acute kidney injury diagnosis technology, a B cell epitope peptide of human NGAL (Neutrophil Gelatinase Associated Lipocalin) and a hybridoma cell prepared by same, and an application of the B cell epitope peptide and a specific antibody thereof and an immune complex of the specific antibody in preparing diagnostic reagent for acute kidney injury. The B cell epitope peptide prepared by the invention immunizes a monoclonal antibody prepared by adopting a rat and has the advantages of high purity (The SDS (Sodium Dodecyl Sulfate)-PAGE (PolyAcrylamide Gel Electrophoresi) detection purity is more than 96 percent), high valence (the ELISA (Enzyme-Linked Immuno Sorbent Assay) valence reaches 1:256000), good specificity, mass preparation and the like; and through the monoclonal antibody and a polyclonal antibody prepared by the B cell epitope peptide, the B cell epitope peptide can be used for detecting the content of the NGAL in the urine of a patient, for example, by adopting a double antibody sandwich ELISA reaction mode, a double antibody sandwich structure formed by an enzyme labeled human anti-NGAL monoclonal antibody, an enzyme labeled plate package anti-NGAL polyclonal antibody and a measured sample NGAL antigen is detected.
Owner:重庆业为基生物科技有限公司
Polypeptide hydrogel with slow-release exosomes and preparation method and application thereof
ActiveCN110229214AProlong and enhance efficacyReduce releaseAerosol deliveryOintment deliveryInflammatory factorsCell-Extracellular Matrix
The invention discloses a polypeptide hydrogel. The polypeptide hydrogel is prepared by mixing a self-assembled peptide (SAP) aqueous solution with exosomes (Exos). The present invention also discloses a preparation method and application of the polypeptide hydrogel. The polypeptide hydrogel provided by the invention can effectively slow down the release of the Exos and prolong the half-life of the Exos; and the released Exos have the activity similar to that of newly-separated Exos, and can effectively reduce HK2 cell injury caused by hypoxia and promote the recovery of vascular endothelial damage. The polypeptide hydrogel disclosed by the invention is capable of effectively reducing acute kidney injury and slowing down renal fibrosis by reducing kidney cell apoptosis and inflammatory factors, the expression amount of kidney injury marker protein-neutrophil gelatinase-related apolipoprotein (NGAL), and the synthesis and secretion of renal extracellular matrix (ECM), and has a good clinical application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
NGAL for reduction and amelioration of ischemic and nephrotoxic injuries
InactiveUS7776824B2Promote lowerReduces high level of serumAntibacterial agentsBiocideIschemic injuryGelatinase
Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1
Transgenic Reporter Mouse and Method for Use
InactiveUS20100122355A1High through-put screeningCompounds screening/testingVectorsMammalFluorescence
A transgenic mammal, including a transgenic mouse, whose genome comprises a transgene, said transgene comprises a neutrophil gelatinase-associated lipocalin (NGAL) promoter gene operably linked to at least one sequence encoding at least one of a fluorescent or bioluminescent protein, wherein the NGAL promoter gene expression in the mouse can be assayed by bioluminescence or fluorescence imaging.
Owner:PARAGAS NEAL +2
Recombinant neutrophil gelatinase associated lipocalin and preparation method of protein antibody
ActiveCN103451187AHigh expressionOvercoming poor specificitySerum immunoglobulinsImmunoglobulins against animals/humansEpitopeWestern blot
The invention discloses recombinant neutrophil gelatinase associated lipocalin and a preparation method thereof. The preparation method of the recombinant neutrophil gelatinase associated lipocalin antibody belonging to the technical fields of biological science and transthyretin comprises the following steps: analyzing an NGAL (neutrophil gelatinase associated lipocalin) epitope; synthesizing the recombinant NGAL; separately purifying the recombinant NGAL; preparing an anti-rabbit recombinant NGAL antibody; collecting and separating to obtain an antiserum purified antibody containing the antibody, so as to obtain the anti-NGAL antibody. By adopting the preparation method, the problem of low yield in preparation of a multi-antibody by a natural full-length protein is solved; meanwhile, the antibody prepared by the preparation technology disclosed by the invention has good specificity; the problem that the traditional neutrophil gelatinase associated lipocalin antibody cannot completely meet a western blot immunohistochemical experiment and an enzyme-linked immunosorbent assay is also solved.
Owner:CUSABIO TECH LLC
Hybridoma cell strain generating anti-human NGAL specific monoclonal antibody, monoclonal antibody generated by same and application
InactiveCN103074303AImmunoglobulins against animals/humansMicroorganism based processesBALB/cNGAL Protein
The invention discloses a hybridoma cell strain generating an anti-human NGAL specific monoclonal antibody and a monoclonal antibody generated by the same. The hybridoma cell strain is generated in a way that after an amino acid sequence shown by SEQIDNO:1 immunizes a Balb / c rat, a spleen B lymph cell and a myeloma cell of the rat are fused for further cultivation. The antibody can be used for the immunity detection of the NGAL. Based on the invention, an immunity detection reagent for the NGAL can be developed and used for diagnosing and detecting acute kidney injury and other diseases.
Owner:ARMY MEDICAL UNIV
Lactic bacteria useful as probiotics
InactiveUS7927584B2Pleasant flavorHealthy digestion and intestineBiocideBacterial antigen ingredientsDiseaseMetabolite
Owner:ALLENDE MIGUEL ANGEL GARCIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com